Nanjing Leads Biolabs Co., Ltd. (09887.HK)株価、チャート、ニュース、およびAI分析

Q: LEADS BIOLABS-B の株価パフォーマンスは？

LEADS BIOLABS-B の現在の価格は $56.5 で、最終取引日から 2.63% 増加 変動しました。

Q: Nanjing Leads Biolabs Co., Ltd. の主な事業テーマや業界は？

Nanjing Leads Biolabs Co., Ltd. は Biotechnology 業界、セクターは Health Care に属しています。

Q: Nanjing Leads Biolabs Co., Ltd. の時価総額はいくらですか？

Nanjing Leads Biolabs Co., Ltd. の現在の時価総額は $8.6B です。

ホーム

株式

09887.HK

LEADS BIOLABS-B (09887.HK)

Nanjing Leads Biolabs Co., Ltd.

HK$56.5

2.63%

$1.45

休場: Jan 16, 16:00:00 HKT

主要データ

前終値

$55.7

始値

$55.05

当日レンジ

$55 - $57.15

52週レンジ

$44.72 - $83.6

取引高

259.9K

平均取引高

590.5K

1株当たり利益(TTM)

-1.70

配当利回り

時価総額

$8.6B

LEADS BIOLABS-Bとは何ですか？

Nanjing Leads Biolabs Co., Ltd. operates as a pharmaceutical company. The company is headquartered in Nanjing, Jiangsu and currently employs 192 full-time employees. The company went IPO on 2025-07-25. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The firm's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The firm has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The firm mainly conducts its business in the domestic market.

特徴

取引戦略